The Daily Start-Up (March 2, 2020)
Wall Street Journal (blog) - Scott Austin

...Seven venture firms tied with three companies apiece: Bessemer Venture Partners, Duff Ackerman & Goodrich, Flagship Ventures, Kleiner Perkins Caufield ... Read the full post online

On Friday, April 9, the MIT Sloan community will welcome Anatoly Chubais, Chairman and CEO of RUSNANO. RUSNANO is Russia's state-owned nanotechnology firm and was one of several firms created in 2007 to jump-start investment in non-energy sectors. Mr. Chubais has also played an important role in the launch of the SKOLKOVO Moscow School of Management where MIT Sloan has been involved in a major collaboration. Mr.

Xconomy.com
Gregory T. Huang 5/12/10

Posted by Scott Kirsner
Boston.com

May 18, 2010 09:16 AM

Life Science Company Presents Data at Advances in Genome Biology and Technology Meeting

Life Science Company Continues to Define a New Category in Sequencing

Gibbstown, NJ, and Waltham, MA – EMD Chemicals, Inc. (EMD), a subsidiary of Merck KGaA, Darmstadt, Germany, and Epitome Biosystems, Inc, announced today that EMD has launched WideScreen™ EpiTag™ ERK Pathway Assays, the first wave of bead-based, multiplex assays using EpiTag™ Technology licensed from Epitome Biosystems. The new line of assays will enable researchers to make quantitative, highly multiplexed measurements of important cell targets, greatly facilitating drug discovery efforts.

WALTHAM, Mass. & COPENHAGEN, Denmark - BG Medicine today announced that it has entered into a research collaboration agreement with the Copenhagen General Population Study with the goals to discover and validate novel cardiovascular biomarkers, including those predictive of rupture of atherosclerotic plaque and myocardial infarction. The planned research, which will be conducted as part of BG Medicine’s High Risk Plaque (HRP) Initiative, will apply BG Medicine’s proprietary proteomic and metabolomic discovery platform capabilities.

CAMBRIDGE, Mass. & SUMMIT, N.J.--(BUSINESS WIRE)--Acceleron Pharma, Inc. and Celgene Corporation today announced a worldwide strategic collaboration for the joint development and commercialization of ACE-011, a first-in-class, novel bone-forming compound. The collaboration combines both companies’ resources and commitment to developing products for the treatment of cancer and cancer-related bone loss. In pre-clinical and early clinical studies, this innovative compound has reported success in key biomarkers of bone formation.

CAMBRIDGE, Mass. February 20, 2008 – Genstruct Inc., a systems biology company focused on identifying molecular mechanisms, networks and biomarkers to better understand large scale biology announced today that it has entered into a Master Research Agreement with Pfizer designed to cover current and future collaborations. The first collaboration under this new agreement is in the area of preclinical drug safety, focusing initially on a systems biology analysis of underlying mechanisms of drug-induced liver injury.